Cellipont Bioservices and Secretome Therapeutics are set to enter a collaboration in the manufacture of the latter’s cellular therapy, STM-01.
The collaboration will see Cellipont offering technology transfer, cGMP manufacturing and analytical method transfer for Master Cell Bank therapy.
Go deeper with GlobalData
Cellipont Bioservices CEO Darren Head stated: “This partnership with Secretome Therapeutics represents an exciting opportunity for Cellipont to support the advancement of cutting-edge cell therapies.
“We are very excited to collaborate with a company so dedicated to developing innovative solutions that address significant unmet medical needs and improve patient outcomes.”
STM-01 treats severe cardiovascular diseases: dilated cardiomyopathy (DCM) and heart failure with preserved ejection fraction (HFpEF).
Two Phase I trials are anticipated to begin in the first quarter of 2025 to study the therapy in heart failure patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSTM-01 is protected under a recently granted matter patent composition which also encompasses STM-21.
STM-21 consists of the nCPCs-secreted bioactive molecules, including cytokines and exosomes, known for cellular repair promotion and inflammation reduction.
The therapeutic is being developed for conditions associated with chronic inflammation, such as skin wounds and neurodegenerative conditions, with further preclinical data anticipated in 2025.
Secretome Therapeutics CEO and president Vinny Jindal stated: “A key objective for Secretome in 2025 is to produce STM-01 drug product that is suitable for late-stage clinical testing and potential commercial use.”
The company is at the forefront of developing nCPC-derived therapeutics to address conditions that have limited treatment alternatives currently.
A contract development and manufacturing organisation, Cellipont Bioservices is dedicated to cell therapy advancement and has a history of similar collaborations.
In October 2023, it signed an agreement with Diakonos Oncology to develop a cell therapy, DOC1021, to treat glioblastoma multiforme.
